| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lipoproteins, LDL | 86 | 2022 | 343 | 11.530 |
Why?
|
| Antigen-Antibody Complex | 48 | 2019 | 175 | 7.550 |
Why?
|
| Diabetes Mellitus, Type 1 | 57 | 2022 | 529 | 6.780 |
Why?
|
| Autoantibodies | 23 | 2017 | 434 | 3.800 |
Why?
|
| Macrophages | 40 | 2019 | 647 | 2.860 |
Why?
|
| Diabetic Angiopathies | 31 | 2020 | 203 | 2.660 |
Why?
|
| Diabetic Nephropathies | 14 | 2022 | 161 | 2.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 23 | 2022 | 1085 | 2.270 |
Why?
|
| Atherosclerosis | 14 | 2019 | 204 | 2.150 |
Why?
|
| Lipoproteins | 22 | 2022 | 161 | 2.120 |
Why?
|
| Arteriosclerosis | 28 | 2005 | 137 | 2.010 |
Why?
|
| Endothelium, Vascular | 16 | 2015 | 371 | 1.850 |
Why?
|
| Albuminuria | 11 | 2019 | 171 | 1.830 |
Why?
|
| Lipopolysaccharides | 30 | 2021 | 455 | 1.720 |
Why?
|
| Glycation End Products, Advanced | 13 | 2019 | 125 | 1.690 |
Why?
|
| Cardiovascular Diseases | 13 | 2021 | 940 | 1.650 |
Why?
|
| Sphingolipids | 7 | 2022 | 337 | 1.510 |
Why?
|
| Malondialdehyde | 9 | 2017 | 43 | 1.500 |
Why?
|
| Matrix Metalloproteinase 1 | 18 | 2021 | 74 | 1.480 |
Why?
|
| Inflammation | 17 | 2022 | 1030 | 1.460 |
Why?
|
| Cytokines | 22 | 2021 | 866 | 1.360 |
Why?
|
| E-Selectin | 9 | 2017 | 44 | 1.340 |
Why?
|
| Biomarkers | 19 | 2019 | 1593 | 1.320 |
Why?
|
| Interleukin-6 | 23 | 2019 | 330 | 1.300 |
Why?
|
| Receptors, IgG | 8 | 2017 | 94 | 1.200 |
Why?
|
| Monocytes | 16 | 2015 | 210 | 1.140 |
Why?
|
| Disease Progression | 14 | 2019 | 1038 | 1.140 |
Why?
|
| Receptors, LDL | 17 | 2022 | 72 | 1.120 |
Why?
|
| Humans | 196 | 2022 | 68618 | 1.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2017 | 27 | 1.080 |
Why?
|
| Cholesterol | 31 | 2017 | 331 | 0.960 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 3 | 2017 | 27 | 0.940 |
Why?
|
| Metabolic Syndrome | 8 | 2022 | 191 | 0.900 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2022 | 161 | 0.890 |
Why?
|
| Immunoglobulin G | 11 | 2016 | 481 | 0.880 |
Why?
|
| Alveolar Bone Loss | 7 | 2021 | 40 | 0.860 |
Why?
|
| Kidney | 5 | 2022 | 945 | 0.860 |
Why?
|
| Periodontitis | 6 | 2021 | 47 | 0.840 |
Why?
|
| Tunica Intima | 5 | 2011 | 59 | 0.830 |
Why?
|
| Gene Expression Regulation | 10 | 2018 | 1293 | 0.770 |
Why?
|
| Toll-Like Receptor 4 | 8 | 2015 | 114 | 0.760 |
Why?
|
| Diabetes Mellitus | 18 | 2007 | 694 | 0.760 |
Why?
|
| Tunica Media | 4 | 2010 | 33 | 0.740 |
Why?
|
| Cholesterol Esters | 13 | 2005 | 26 | 0.690 |
Why?
|
| Apolipoproteins | 10 | 2019 | 51 | 0.690 |
Why?
|
| Immunity, Humoral | 2 | 2010 | 42 | 0.690 |
Why?
|
| Plaque, Atherosclerotic | 4 | 2017 | 125 | 0.690 |
Why?
|
| Male | 90 | 2021 | 37321 | 0.670 |
Why?
|
| Carotid Intima-Media Thickness | 6 | 2018 | 54 | 0.670 |
Why?
|
| Chlamydophila pneumoniae | 3 | 2004 | 13 | 0.670 |
Why?
|
| Diabetes Complications | 11 | 2019 | 249 | 0.670 |
Why?
|
| Palmitic Acid | 6 | 2018 | 51 | 0.650 |
Why?
|
| Adult | 67 | 2021 | 21403 | 0.650 |
Why?
|
| NF-kappa B | 11 | 2018 | 432 | 0.630 |
Why?
|
| Up-Regulation | 11 | 2020 | 682 | 0.600 |
Why?
|
| Risk Factors | 25 | 2020 | 5731 | 0.590 |
Why?
|
| Simvastatin | 6 | 2013 | 34 | 0.580 |
Why?
|
| Female | 76 | 2021 | 38074 | 0.580 |
Why?
|
| Coronary Disease | 6 | 2004 | 358 | 0.570 |
Why?
|
| Oxidation-Reduction | 17 | 2009 | 567 | 0.550 |
Why?
|
| Glucose | 10 | 2013 | 307 | 0.530 |
Why?
|
| U937 Cells | 19 | 2013 | 61 | 0.520 |
Why?
|
| Cells, Cultured | 22 | 2018 | 2673 | 0.520 |
Why?
|
| Animals | 45 | 2022 | 20881 | 0.510 |
Why?
|
| Diabetic Neuropathies | 3 | 2021 | 33 | 0.510 |
Why?
|
| Antibodies | 7 | 2010 | 241 | 0.500 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2017 | 52 | 0.500 |
Why?
|
| Apoptosis | 4 | 2018 | 1641 | 0.500 |
Why?
|
| Coronary Artery Disease | 5 | 2016 | 696 | 0.500 |
Why?
|
| Mitogen-Activated Protein Kinases | 7 | 2012 | 250 | 0.500 |
Why?
|
| Lipoproteins, HDL | 14 | 2016 | 113 | 0.500 |
Why?
|
| Renal Insufficiency | 1 | 2016 | 121 | 0.480 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 6 | 2021 | 59 | 0.470 |
Why?
|
| Carotid Arteries | 3 | 2010 | 110 | 0.460 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 7 | 2017 | 58 | 0.450 |
Why?
|
| Lipoproteins, VLDL | 9 | 1993 | 32 | 0.440 |
Why?
|
| Triglycerides | 17 | 2017 | 184 | 0.440 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 4 | 2022 | 87 | 0.430 |
Why?
|
| Diet, High-Fat | 8 | 2022 | 81 | 0.430 |
Why?
|
| Blood Glucose | 15 | 2020 | 631 | 0.420 |
Why?
|
| Adolescent | 27 | 2019 | 8912 | 0.410 |
Why?
|
| Myocardial Infarction | 3 | 2018 | 807 | 0.410 |
Why?
|
| Immunoglobulin M | 4 | 2013 | 172 | 0.410 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2018 | 507 | 0.400 |
Why?
|
| Transcription, Genetic | 5 | 2018 | 562 | 0.400 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 3259 | 0.400 |
Why?
|
| Young Adult | 17 | 2020 | 5717 | 0.400 |
Why?
|
| Middle Aged | 42 | 2021 | 21147 | 0.400 |
Why?
|
| Calcinosis | 2 | 2010 | 241 | 0.390 |
Why?
|
| CD36 Antigens | 3 | 2022 | 9 | 0.380 |
Why?
|
| Cohort Studies | 16 | 2020 | 2358 | 0.380 |
Why?
|
| Transcription Factor AP-1 | 4 | 2009 | 61 | 0.380 |
Why?
|
| Cholesterol, LDL | 11 | 2012 | 161 | 0.380 |
Why?
|
| Receptors, Immunologic | 2 | 2016 | 72 | 0.380 |
Why?
|
| RNA, Messenger | 11 | 2012 | 1664 | 0.380 |
Why?
|
| Collagen Type IV | 1 | 2011 | 28 | 0.380 |
Why?
|
| Glomerular Mesangium | 1 | 2011 | 53 | 0.370 |
Why?
|
| Mesangial Cells | 1 | 2011 | 37 | 0.370 |
Why?
|
| Cell Line | 11 | 2018 | 1752 | 0.370 |
Why?
|
| Mice | 23 | 2022 | 8474 | 0.360 |
Why?
|
| Phagocytes | 3 | 2010 | 15 | 0.360 |
Why?
|
| Ceramides | 5 | 2018 | 578 | 0.360 |
Why?
|
| Antibody Formation | 2 | 2008 | 93 | 0.360 |
Why?
|
| Gene Expression Regulation, Enzymologic | 5 | 2011 | 282 | 0.350 |
Why?
|
| Macrophage Activation | 6 | 2010 | 75 | 0.350 |
Why?
|
| Lysophospholipids | 3 | 2018 | 209 | 0.350 |
Why?
|
| Sphingosine | 3 | 2018 | 315 | 0.330 |
Why?
|
| Carotid Artery, Internal | 2 | 2006 | 85 | 0.330 |
Why?
|
| Sphingomyelin Phosphodiesterase | 4 | 2021 | 183 | 0.320 |
Why?
|
| Periodontal Diseases | 4 | 2013 | 54 | 0.320 |
Why?
|
| Lysine | 3 | 2005 | 96 | 0.320 |
Why?
|
| Glycosylation | 7 | 2019 | 185 | 0.320 |
Why?
|
| Insulin | 11 | 2015 | 619 | 0.320 |
Why?
|
| Fatty Acids | 3 | 2018 | 222 | 0.320 |
Why?
|
| Palmitates | 2 | 2018 | 20 | 0.320 |
Why?
|
| Fibroblasts | 7 | 2016 | 902 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2019 | 626 | 0.300 |
Why?
|
| Matrix Metalloproteinase 9 | 5 | 2017 | 160 | 0.300 |
Why?
|
| Hyperlipidemias | 4 | 2022 | 90 | 0.300 |
Why?
|
| Enzyme Inhibitors | 5 | 2019 | 659 | 0.290 |
Why?
|
| Endothelial Cells | 4 | 2018 | 384 | 0.280 |
Why?
|
| Nerve Growth Factors | 2 | 2019 | 75 | 0.280 |
Why?
|
| Connective Tissue Growth Factor | 4 | 2018 | 76 | 0.270 |
Why?
|
| Foam Cells | 6 | 2008 | 26 | 0.270 |
Why?
|
| Time Factors | 13 | 2016 | 4655 | 0.270 |
Why?
|
| Liver | 3 | 2022 | 1118 | 0.270 |
Why?
|
| Reference Values | 13 | 2009 | 579 | 0.260 |
Why?
|
| Adipocytes | 3 | 2011 | 88 | 0.260 |
Why?
|
| Cholesterol, HDL | 10 | 2008 | 112 | 0.260 |
Why?
|
| Eye Proteins | 2 | 2019 | 160 | 0.260 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 3 | 2014 | 18 | 0.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2013 | 212 | 0.260 |
Why?
|
| Osteoclasts | 5 | 2021 | 132 | 0.250 |
Why?
|
| Haptoglobins | 2 | 2016 | 12 | 0.250 |
Why?
|
| Complement System Proteins | 1 | 2006 | 135 | 0.250 |
Why?
|
| Serpins | 2 | 2019 | 205 | 0.250 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 2016 | 195 | 0.250 |
Why?
|
| Immunoglobulin Isotypes | 5 | 2009 | 28 | 0.250 |
Why?
|
| Protein Kinase C | 2 | 2003 | 270 | 0.240 |
Why?
|
| Mice, Knockout | 9 | 2022 | 1692 | 0.240 |
Why?
|
| Antibodies, Heterophile | 1 | 2004 | 11 | 0.240 |
Why?
|
| Regression Analysis | 5 | 2018 | 737 | 0.240 |
Why?
|
| Apolipoproteins E | 4 | 2013 | 92 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 63 | 0.230 |
Why?
|
| Hypoglycemic Agents | 6 | 2020 | 362 | 0.230 |
Why?
|
| Immunoblotting | 5 | 2018 | 254 | 0.230 |
Why?
|
| Epitopes | 3 | 2016 | 146 | 0.230 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2001 | 138 | 0.230 |
Why?
|
| Incidence | 4 | 2020 | 1603 | 0.230 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 139 | 0.230 |
Why?
|
| Phenylethyl Alcohol | 1 | 2003 | 9 | 0.220 |
Why?
|
| Dyslipidemias | 4 | 2020 | 98 | 0.220 |
Why?
|
| Iron | 1 | 2005 | 197 | 0.220 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2018 | 201 | 0.220 |
Why?
|
| Transcription Factors | 3 | 2008 | 753 | 0.210 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 199 | 0.210 |
Why?
|
| Phagocytosis | 2 | 2013 | 65 | 0.210 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 1465 | 0.210 |
Why?
|
| Apolipoproteins M | 1 | 2022 | 5 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2009 | 1745 | 0.210 |
Why?
|
| Diabetic Retinopathy | 2 | 2014 | 110 | 0.210 |
Why?
|
| Rabbits | 6 | 2005 | 509 | 0.210 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2007 | 50 | 0.210 |
Why?
|
| Prostaglandin D2 | 1 | 2002 | 21 | 0.200 |
Why?
|
| Inflammation Mediators | 5 | 2015 | 244 | 0.200 |
Why?
|
| Lactosylceramides | 1 | 2022 | 27 | 0.200 |
Why?
|
| Interleukin-8 | 1 | 2002 | 71 | 0.200 |
Why?
|
| Blood Pressure | 6 | 2020 | 1451 | 0.200 |
Why?
|
| Lymphocyte Antigen 96 | 2 | 2013 | 10 | 0.200 |
Why?
|
| Intracranial Arteriosclerosis | 2 | 2014 | 134 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2011 | 124 | 0.200 |
Why?
|
| Apolipoproteins B | 5 | 2004 | 29 | 0.200 |
Why?
|
| Interleukin-1beta | 4 | 2016 | 88 | 0.200 |
Why?
|
| Receptors, Lysosphingolipid | 3 | 2018 | 63 | 0.200 |
Why?
|
| Interferon-gamma | 5 | 2019 | 241 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2011 | 230 | 0.200 |
Why?
|
| Apolipoproteins A | 3 | 1999 | 10 | 0.200 |
Why?
|
| C-Reactive Protein | 5 | 2017 | 180 | 0.190 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2008 | 146 | 0.190 |
Why?
|
| Gingiva | 3 | 2016 | 34 | 0.190 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 166 | 0.190 |
Why?
|
| Enzyme Activation | 5 | 2018 | 791 | 0.190 |
Why?
|
| Uric Acid | 1 | 2021 | 37 | 0.190 |
Why?
|
| Signal Transduction | 12 | 2016 | 2689 | 0.190 |
Why?
|
| Carotid Stenosis | 2 | 2020 | 163 | 0.190 |
Why?
|
| Immunologic Factors | 1 | 2002 | 87 | 0.190 |
Why?
|
| Uracil | 2 | 2011 | 18 | 0.190 |
Why?
|
| Flow Cytometry | 3 | 2011 | 489 | 0.190 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2011 | 14 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 6 | 2002 | 196 | 0.190 |
Why?
|
| Case-Control Studies | 7 | 2008 | 1553 | 0.190 |
Why?
|
| Stroke | 4 | 2020 | 2163 | 0.190 |
Why?
|
| Piperidines | 2 | 2011 | 123 | 0.180 |
Why?
|
| Niemann-Pick Disease, Type A | 1 | 2020 | 1 | 0.180 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2010 | 175 | 0.180 |
Why?
|
| Fatty Liver | 1 | 2020 | 97 | 0.180 |
Why?
|
| Amitriptyline | 1 | 2019 | 11 | 0.180 |
Why?
|
| Autoimmunity | 3 | 2002 | 118 | 0.180 |
Why?
|
| MAP Kinase Signaling System | 4 | 2011 | 247 | 0.170 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 4 | 2017 | 45 | 0.170 |
Why?
|
| Aorta | 5 | 2016 | 316 | 0.170 |
Why?
|
| Neoplasm Proteins | 2 | 2008 | 307 | 0.170 |
Why?
|
| Chemokine CCL2 | 2 | 2017 | 101 | 0.170 |
Why?
|
| Risk Assessment | 5 | 2014 | 2007 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 792 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 194 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2011 | 710 | 0.170 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2019 | 5 | 0.170 |
Why?
|
| Thiazolidinediones | 4 | 2013 | 77 | 0.170 |
Why?
|
| Kallikreins | 1 | 2020 | 323 | 0.170 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 107 | 0.170 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 167 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2015 | 346 | 0.160 |
Why?
|
| Esophageal Achalasia | 1 | 2019 | 78 | 0.160 |
Why?
|
| X-Ray Microtomography | 4 | 2021 | 50 | 0.160 |
Why?
|
| Life Style | 1 | 2020 | 338 | 0.160 |
Why?
|
| Docosahexaenoic Acids | 1 | 2018 | 12 | 0.160 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 1046 | 0.150 |
Why?
|
| Histiocytes | 3 | 2008 | 8 | 0.150 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 1054 | 0.150 |
Why?
|
| Cross-Sectional Studies | 8 | 2018 | 2279 | 0.150 |
Why?
|
| Insulin Resistance | 6 | 2020 | 241 | 0.150 |
Why?
|
| Gene Expression | 3 | 2017 | 770 | 0.150 |
Why?
|
| Hemocyanins | 2 | 2008 | 14 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2000 | 597 | 0.150 |
Why?
|
| Blood Platelets | 9 | 1995 | 284 | 0.150 |
Why?
|
| Umbilical Veins | 5 | 2003 | 54 | 0.150 |
Why?
|
| Interleukin-1 | 3 | 2006 | 86 | 0.140 |
Why?
|
| Immediate-Early Proteins | 2 | 2008 | 63 | 0.140 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2016 | 18 | 0.140 |
Why?
|
| Chemokines | 2 | 2008 | 119 | 0.140 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2016 | 15 | 0.140 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1997 | 43 | 0.140 |
Why?
|
| Caspase 3 | 1 | 2017 | 233 | 0.140 |
Why?
|
| Smoking | 3 | 2020 | 1452 | 0.140 |
Why?
|
| Hepatocytes | 1 | 2018 | 205 | 0.140 |
Why?
|
| Collagenases | 3 | 2001 | 34 | 0.140 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 48 | 0.140 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 318 | 0.140 |
Why?
|
| Disease Models, Animal | 7 | 2021 | 2550 | 0.140 |
Why?
|
| United States | 6 | 2018 | 7367 | 0.130 |
Why?
|
| In Vitro Techniques | 7 | 1997 | 765 | 0.130 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2015 | 4 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 240 | 0.130 |
Why?
|
| Lipids | 5 | 2015 | 298 | 0.130 |
Why?
|
| Hypolipidemic Agents | 3 | 2007 | 82 | 0.130 |
Why?
|
| Prekallikrein | 1 | 2015 | 66 | 0.130 |
Why?
|
| Drug Synergism | 5 | 2018 | 260 | 0.130 |
Why?
|
| Logistic Models | 4 | 2016 | 1420 | 0.130 |
Why?
|
| Aged | 16 | 2020 | 14862 | 0.130 |
Why?
|
| Osmolar Concentration | 3 | 2010 | 134 | 0.130 |
Why?
|
| Hypertension | 4 | 2020 | 1535 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2010 | 615 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2013 | 234 | 0.120 |
Why?
|
| American Heart Association | 1 | 2015 | 142 | 0.120 |
Why?
|
| Cholesterol, VLDL | 5 | 1996 | 17 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 1753 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2017 | 307 | 0.120 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 2011 | 15 | 0.120 |
Why?
|
| Platelet Aggregation | 10 | 1995 | 127 | 0.120 |
Why?
|
| Homocysteine | 1 | 2014 | 28 | 0.120 |
Why?
|
| Prognosis | 4 | 2013 | 2093 | 0.120 |
Why?
|
| Cell Survival | 4 | 2014 | 901 | 0.120 |
Why?
|
| Immunoassay | 2 | 2013 | 64 | 0.120 |
Why?
|
| Bacterial Infections | 2 | 1993 | 163 | 0.120 |
Why?
|
| Glycerol Kinase | 1 | 2013 | 3 | 0.120 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 1 | 2013 | 6 | 0.120 |
Why?
|
| Rhodobacter sphaeroides | 1 | 2013 | 6 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2010 | 786 | 0.110 |
Why?
|
| Lymphocytes | 2 | 1991 | 228 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2019 | 3705 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 2791 | 0.110 |
Why?
|
| Veterans | 3 | 2019 | 904 | 0.110 |
Why?
|
| Capillaries | 1 | 2014 | 105 | 0.110 |
Why?
|
| Research Design | 2 | 2020 | 729 | 0.110 |
Why?
|
| Ultrasonography | 3 | 2010 | 453 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 4 | 2019 | 274 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 546 | 0.110 |
Why?
|
| Pericytes | 1 | 2014 | 81 | 0.110 |
Why?
|
| Transcriptional Activation | 3 | 2005 | 226 | 0.110 |
Why?
|
| Interleukin-12 | 2 | 2019 | 75 | 0.110 |
Why?
|
| RNA | 2 | 2011 | 171 | 0.110 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 140 | 0.110 |
Why?
|
| Cross Reactions | 2 | 2004 | 57 | 0.110 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2012 | 23 | 0.100 |
Why?
|
| South Carolina | 3 | 2016 | 2752 | 0.100 |
Why?
|
| Stents | 2 | 2016 | 657 | 0.100 |
Why?
|
| Retina | 1 | 2014 | 252 | 0.100 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Eicosapentaenoic Acid | 1 | 1991 | 9 | 0.100 |
Why?
|
| Matrix Metalloproteinases | 2 | 2021 | 223 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2012 | 82 | 0.100 |
Why?
|
| Fish Oils | 1 | 1991 | 21 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2012 | 110 | 0.100 |
Why?
|
| Blood Vessels | 1 | 1992 | 102 | 0.100 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 2022 | 48 | 0.100 |
Why?
|
| Paracrine Communication | 1 | 2011 | 31 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 331 | 0.100 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2011 | 34 | 0.100 |
Why?
|
| Age of Onset | 3 | 2018 | 188 | 0.100 |
Why?
|
| Copper | 2 | 2005 | 149 | 0.100 |
Why?
|
| Hyperglycemia | 4 | 2011 | 158 | 0.090 |
Why?
|
| Lipid Peroxidation | 2 | 2005 | 94 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 174 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2018 | 209 | 0.090 |
Why?
|
| Antibody Specificity | 2 | 2004 | 98 | 0.090 |
Why?
|
| Receptors, Scavenger | 2 | 2014 | 13 | 0.090 |
Why?
|
| Lipoproteins, HDL2 | 1 | 2010 | 4 | 0.090 |
Why?
|
| Lipoproteins, HDL3 | 1 | 2010 | 4 | 0.090 |
Why?
|
| Methionine | 2 | 2008 | 36 | 0.090 |
Why?
|
| Body Mass Index | 4 | 2016 | 867 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2010 | 627 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2010 | 71 | 0.090 |
Why?
|
| Apolipoprotein A-I | 2 | 2008 | 29 | 0.090 |
Why?
|
| Osteopontin | 1 | 2009 | 28 | 0.090 |
Why?
|
| Child | 9 | 2018 | 6405 | 0.090 |
Why?
|
| Flavonoids | 3 | 2010 | 109 | 0.090 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2010 | 42 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 852 | 0.090 |
Why?
|
| Interleukin-10 | 2 | 2010 | 144 | 0.090 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 15 | 0.090 |
Why?
|
| Magnesium Oxide | 1 | 1989 | 2 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 320 | 0.080 |
Why?
|
| Phospholipids | 3 | 1996 | 108 | 0.080 |
Why?
|
| Proteinuria | 3 | 1979 | 136 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2016 | 1342 | 0.080 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2009 | 15 | 0.080 |
Why?
|
| Sweetening Agents | 1 | 2009 | 23 | 0.080 |
Why?
|
| STAT1 Transcription Factor | 1 | 2008 | 35 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2009 | 86 | 0.080 |
Why?
|
| Random Allocation | 3 | 2011 | 442 | 0.080 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 240 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2015 | 931 | 0.080 |
Why?
|
| RNA Interference | 3 | 2018 | 266 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2008 | 41 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 1989 | 186 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 80 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2016 | 880 | 0.080 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2008 | 77 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2020 | 7029 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 1991 | 514 | 0.080 |
Why?
|
| Sphingomyelins | 2 | 2018 | 106 | 0.070 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2010 | 59 | 0.070 |
Why?
|
| Protein Transport | 3 | 2014 | 280 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 25 | 0.070 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2006 | 11 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2000 | 511 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 492 | 0.070 |
Why?
|
| Prevalence | 4 | 2013 | 1619 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2010 | 718 | 0.070 |
Why?
|
| Antibodies, Blocking | 2 | 2013 | 17 | 0.070 |
Why?
|
| Risk | 2 | 2003 | 563 | 0.070 |
Why?
|
| Blood Coagulation | 2 | 2017 | 123 | 0.070 |
Why?
|
| Genotype | 3 | 2016 | 786 | 0.070 |
Why?
|
| Coculture Techniques | 3 | 2011 | 147 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 498 | 0.070 |
Why?
|
| Calibration | 2 | 2003 | 73 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2008 | 525 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 2223 | 0.060 |
Why?
|
| Sodium Lactate | 1 | 2005 | 2 | 0.060 |
Why?
|
| Microvessels | 2 | 2018 | 43 | 0.060 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 434 | 0.060 |
Why?
|
| Culture Media | 2 | 2001 | 155 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2010 | 866 | 0.060 |
Why?
|
| Fenofibrate | 2 | 2007 | 23 | 0.060 |
Why?
|
| Collagen | 2 | 2015 | 636 | 0.060 |
Why?
|
| Culture Media, Conditioned | 2 | 2008 | 78 | 0.060 |
Why?
|
| Complement Activation | 1 | 2006 | 145 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2008 | 448 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2021 | 145 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 848 | 0.060 |
Why?
|
| RANK Ligand | 2 | 2014 | 73 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 1995 | 31 | 0.060 |
Why?
|
| Rats | 5 | 2016 | 5300 | 0.060 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2003 | 9 | 0.060 |
Why?
|
| Chlamydophila Infections | 1 | 2003 | 6 | 0.060 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2003 | 18 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2016 | 291 | 0.060 |
Why?
|
| Caffeic Acids | 1 | 2003 | 9 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2003 | 60 | 0.060 |
Why?
|
| Sulfones | 1 | 2003 | 45 | 0.050 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 189 | 0.050 |
Why?
|
| Binding, Competitive | 2 | 1995 | 165 | 0.050 |
Why?
|
| Nitriles | 1 | 2003 | 68 | 0.050 |
Why?
|
| Fibrinolysis | 3 | 2017 | 55 | 0.050 |
Why?
|
| Obesity | 5 | 2014 | 1076 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2019 | 447 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2003 | 191 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2003 | 161 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2003 | 101 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 839 | 0.050 |
Why?
|
| Immunochemistry | 2 | 2000 | 17 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2003 | 235 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2014 | 499 | 0.050 |
Why?
|
| C-Peptide | 3 | 1996 | 23 | 0.050 |
Why?
|
| Imipramine | 1 | 2021 | 44 | 0.050 |
Why?
|
| Schwann Cells | 1 | 2021 | 33 | 0.050 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2013 | 85 | 0.050 |
Why?
|
| Comorbidity | 3 | 2014 | 1426 | 0.050 |
Why?
|
| Oleic Acid | 2 | 1992 | 40 | 0.050 |
Why?
|
| Calcium | 2 | 2016 | 929 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 66 | 0.050 |
Why?
|
| Oleic Acids | 2 | 1992 | 40 | 0.050 |
Why?
|
| Quercetin | 1 | 2001 | 16 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2005 | 2077 | 0.050 |
Why?
|
| Tretinoin | 1 | 2002 | 92 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 782 | 0.050 |
Why?
|
| Body Weight | 2 | 2020 | 554 | 0.050 |
Why?
|
| Fatty Acid-Binding Protein 7 | 1 | 2000 | 6 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2001 | 17 | 0.050 |
Why?
|
| Cysteine | 2 | 2016 | 112 | 0.050 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2000 | 30 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2003 | 954 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2000 | 43 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 371 | 0.050 |
Why?
|
| Hepatitis | 1 | 2020 | 25 | 0.050 |
Why?
|
| Antioxidants | 2 | 2009 | 304 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 2324 | 0.050 |
Why?
|
| Creatinine | 3 | 2013 | 243 | 0.050 |
Why?
|
| Lysosomes | 2 | 2012 | 136 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 1851 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2001 | 282 | 0.050 |
Why?
|
| Cardiolipins | 1 | 2000 | 12 | 0.050 |
Why?
|
| Hypertriglyceridemia | 1 | 2000 | 21 | 0.050 |
Why?
|
| Absorption | 1 | 2000 | 49 | 0.050 |
Why?
|
| Lipid Metabolism | 3 | 2013 | 186 | 0.050 |
Why?
|
| HIV Protease Inhibitors | 1 | 2000 | 25 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2020 | 114 | 0.040 |
Why?
|
| Protein Binding | 1 | 2003 | 1027 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 246 | 0.040 |
Why?
|
| Benzylidene Compounds | 1 | 2019 | 16 | 0.040 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 31 | 0.040 |
Why?
|
| Caseins | 1 | 1999 | 19 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2001 | 1200 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 317 | 0.040 |
Why?
|
| Cattle | 1 | 2001 | 475 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 52 | 0.040 |
Why?
|
| Mass Spectrometry | 2 | 2013 | 284 | 0.040 |
Why?
|
| Pennsylvania | 1 | 1999 | 46 | 0.040 |
Why?
|
| Nephrosis, Lipoid | 1 | 1979 | 9 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 1999 | 234 | 0.040 |
Why?
|
| Interleukin-23 | 1 | 2019 | 13 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.040 |
Why?
|
| Curcumin | 2 | 2010 | 23 | 0.040 |
Why?
|
| Cell Communication | 2 | 2009 | 116 | 0.040 |
Why?
|
| Glomerulonephritis | 1 | 1979 | 77 | 0.040 |
Why?
|
| Interleukins | 1 | 2019 | 79 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 248 | 0.040 |
Why?
|
| Interleukin-17 | 1 | 2019 | 62 | 0.040 |
Why?
|
| Tyrosine | 1 | 1999 | 196 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 1999 | 79 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2018 | 160 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2018 | 42 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 2018 | 74 | 0.040 |
Why?
|
| Receptors, Lipoprotein | 2 | 1989 | 11 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2018 | 144 | 0.040 |
Why?
|
| Sterols | 2 | 1992 | 13 | 0.040 |
Why?
|
| Immunoglobulins | 2 | 1996 | 97 | 0.040 |
Why?
|
| Mutation | 1 | 2003 | 1213 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2017 | 87 | 0.040 |
Why?
|
| von Willebrand Factor | 4 | 1985 | 47 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 4848 | 0.040 |
Why?
|
| Hypercholesterolemia | 3 | 1987 | 86 | 0.040 |
Why?
|
| Neutrophils | 2 | 1991 | 204 | 0.040 |
Why?
|
| Bacteroidaceae Infections | 1 | 2016 | 15 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 1989 | 248 | 0.030 |
Why?
|
| Virus Diseases | 2 | 1987 | 31 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2016 | 14 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2016 | 122 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 39 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2018 | 368 | 0.030 |
Why?
|
| Blood Specimen Collection | 1 | 1996 | 17 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 137 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 210 | 0.030 |
Why?
|
| Porphyromonas gingivalis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 1026 | 0.030 |
Why?
|
| Glycosphingolipids | 1 | 2016 | 51 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2011 | 1851 | 0.030 |
Why?
|
| Immune System | 1 | 1996 | 63 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 196 | 0.030 |
Why?
|
| Amino Acids | 1 | 2016 | 131 | 0.030 |
Why?
|
| Phenotype | 1 | 1999 | 947 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 326 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1995 | 73 | 0.030 |
Why?
|
| Nitroblue Tetrazolium | 1 | 1995 | 2 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 1996 | 87 | 0.030 |
Why?
|
| Vitamins | 1 | 1996 | 134 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2017 | 152 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1056 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2014 | 23 | 0.030 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 498 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2014 | 26 | 0.030 |
Why?
|
| Factor VIII | 2 | 1985 | 27 | 0.030 |
Why?
|
| Retinal Vasculitis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Blood Coagulation Factors | 2 | 1985 | 44 | 0.030 |
Why?
|
| Role | 1 | 2014 | 25 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2014 | 181 | 0.030 |
Why?
|
| Antigens | 2 | 1985 | 90 | 0.030 |
Why?
|
| Hyperhomocysteinemia | 1 | 2014 | 15 | 0.030 |
Why?
|
| Solubility | 2 | 2009 | 134 | 0.030 |
Why?
|
| Rats, Zucker | 1 | 2013 | 10 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 151 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2014 | 42 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 1174 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 521 | 0.030 |
Why?
|
| Hypoadrenocorticism, Familial | 1 | 2013 | 3 | 0.030 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 2013 | 22 | 0.030 |
Why?
|
| Maxillary Diseases | 1 | 2013 | 13 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2013 | 48 | 0.030 |
Why?
|
| Acid Phosphatase | 1 | 2013 | 36 | 0.030 |
Why?
|
| Gingivitis | 1 | 2013 | 16 | 0.030 |
Why?
|
| Endothelium | 4 | 1987 | 98 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 17 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 101 | 0.030 |
Why?
|
| Leukocytes | 1 | 2013 | 99 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 56 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 99 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1979 | 272 | 0.030 |
Why?
|
| Age Factors | 2 | 2014 | 1864 | 0.030 |
Why?
|
| Apolipoproteins C | 1 | 1993 | 15 | 0.030 |
Why?
|
| Metformin | 1 | 2013 | 63 | 0.030 |
Why?
|
| Leukapheresis | 1 | 1992 | 8 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 120 | 0.030 |
Why?
|
| Erythrocytes | 2 | 1991 | 137 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2014 | 328 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2013 | 308 | 0.030 |
Why?
|
| Skin | 1 | 1995 | 451 | 0.030 |
Why?
|
| DNA | 2 | 2008 | 597 | 0.030 |
Why?
|
| Tetanus Toxoid | 1 | 1991 | 11 | 0.030 |
Why?
|
| Membrane Fluidity | 1 | 1991 | 13 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 27 | 0.030 |
Why?
|
| CD3 Complex | 1 | 1991 | 35 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 16 | 0.020 |
Why?
|
| Models, Biological | 1 | 1996 | 981 | 0.020 |
Why?
|
| Chloroquine | 1 | 1991 | 21 | 0.020 |
Why?
|
| Exosomes | 1 | 2012 | 44 | 0.020 |
Why?
|
| Sterol O-Acyltransferase | 1 | 1991 | 7 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 236 | 0.020 |
Why?
|
| Esterification | 1 | 1991 | 25 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2013 | 307 | 0.020 |
Why?
|
| Thromboxane B2 | 2 | 1988 | 108 | 0.020 |
Why?
|
| RNA Stability | 1 | 2011 | 55 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 30 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1991 | 19 | 0.020 |
Why?
|
| Child, Preschool | 4 | 1983 | 3187 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1991 | 133 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 658 | 0.020 |
Why?
|
| Proteomics | 1 | 2013 | 246 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1991 | 135 | 0.020 |
Why?
|
| gamma-Globulins | 1 | 1970 | 8 | 0.020 |
Why?
|
| Penicillamine | 1 | 1970 | 10 | 0.020 |
Why?
|
| Smad1 Protein | 1 | 2010 | 10 | 0.020 |
Why?
|
| Endosomes | 1 | 2010 | 45 | 0.020 |
Why?
|
| 3T3-L1 Cells | 1 | 2010 | 30 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2010 | 65 | 0.020 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 2 | 1987 | 2 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 43 | 0.020 |
Why?
|
| Poly I-C | 2 | 1987 | 20 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 1970 | 73 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 207 | 0.020 |
Why?
|
| Immunoelectrophoresis | 4 | 1980 | 16 | 0.020 |
Why?
|
| Apoproteins | 1 | 1989 | 11 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 159 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 951 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2009 | 60 | 0.020 |
Why?
|
| Particle Size | 1 | 2010 | 201 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 150 | 0.020 |
Why?
|
| Periodontal Index | 1 | 2009 | 10 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2010 | 85 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 147 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 279 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 134 | 0.020 |
Why?
|
| Diarrhea | 1 | 1989 | 63 | 0.020 |
Why?
|
| Imidazoles | 1 | 2009 | 175 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 536 | 0.020 |
Why?
|
| Gingival Crevicular Fluid | 1 | 2008 | 9 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 2083 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 195 | 0.020 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2008 | 22 | 0.020 |
Why?
|
| Alleles | 1 | 2009 | 386 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 1015 | 0.020 |
Why?
|
| Molecular Weight | 3 | 1977 | 358 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2010 | 295 | 0.020 |
Why?
|
| Pyridines | 1 | 2009 | 261 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 742 | 0.020 |
Why?
|
| Hyperlipoproteinemias | 1 | 1987 | 2 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 306 | 0.020 |
Why?
|
| Transplantation | 1 | 1987 | 23 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2008 | 155 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2007 | 34 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 7 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 179 | 0.020 |
Why?
|
| Cats | 1 | 1987 | 292 | 0.020 |
Why?
|
| Body Constitution | 1 | 2006 | 24 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 3 | 1981 | 6 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1986 | 94 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 201 | 0.020 |
Why?
|
| Phosphatidylethanolamines | 1 | 1985 | 20 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1985 | 38 | 0.020 |
Why?
|
| Insulin Infusion Systems | 1 | 1985 | 27 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1083 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2008 | 483 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 114 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2006 | 144 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1989 | 1738 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 245 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 274 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2007 | 382 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 320 | 0.020 |
Why?
|
| Adiponectin | 1 | 2004 | 52 | 0.020 |
Why?
|
| Immunodiffusion | 2 | 1976 | 19 | 0.010 |
Why?
|
| Brain | 1 | 2014 | 2176 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1986 | 402 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 384 | 0.010 |
Why?
|
| Chromans | 1 | 2003 | 12 | 0.010 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2003 | 11 | 0.010 |
Why?
|
| Platelet Activating Factor | 1 | 1983 | 34 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2014 | 7277 | 0.010 |
Why?
|
| Insulin Antibodies | 1 | 1981 | 2 | 0.010 |
Why?
|
| Sex Factors | 2 | 1983 | 1266 | 0.010 |
Why?
|
| Thrombosis | 1 | 2002 | 218 | 0.010 |
Why?
|
| Mixed Function Oxygenases | 1 | 2000 | 35 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2000 | 22 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2000 | 62 | 0.010 |
Why?
|
| Adosterol | 1 | 1980 | 1 | 0.010 |
Why?
|
| Cushing Syndrome | 1 | 1980 | 7 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1980 | 46 | 0.010 |
Why?
|
| Hypopituitarism | 1 | 1979 | 5 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1980 | 119 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1987 | 1615 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1979 | 24 | 0.010 |
Why?
|
| Muramidase | 1 | 1979 | 38 | 0.010 |
Why?
|
| Quality Control | 1 | 1998 | 81 | 0.010 |
Why?
|
| Reference Standards | 1 | 1998 | 115 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1979 | 120 | 0.010 |
Why?
|
| Bence Jones Protein | 1 | 1978 | 1 | 0.010 |
Why?
|
| Heavy Chain Disease | 1 | 1977 | 1 | 0.010 |
Why?
|
| Immunoglobulin delta-Chains | 1 | 1977 | 1 | 0.010 |
Why?
|
| Phosphotungstic Acid | 1 | 1977 | 1 | 0.010 |
Why?
|
| Paraproteins | 1 | 1977 | 2 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 1977 | 10 | 0.010 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 1977 | 10 | 0.010 |
Why?
|
| Chemical Precipitation | 1 | 1977 | 14 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1977 | 19 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 1977 | 22 | 0.010 |
Why?
|
| Methods | 1 | 1977 | 156 | 0.010 |
Why?
|
| Manganese | 1 | 1977 | 26 | 0.010 |
Why?
|
| Research | 1 | 1998 | 214 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1977 | 72 | 0.010 |
Why?
|
| Magnesium | 1 | 1977 | 110 | 0.010 |
Why?
|
| Hypolipoproteinemias | 1 | 1976 | 1 | 0.010 |
Why?
|
| Lymphoma | 1 | 1977 | 116 | 0.010 |
Why?
|
| Heparin | 1 | 1977 | 205 | 0.010 |
Why?
|
| Platelet Activation | 1 | 1995 | 24 | 0.010 |
Why?
|
| Arachidonic Acid | 2 | 1985 | 86 | 0.010 |
Why?
|
| beta-Thromboglobulin | 1 | 1994 | 7 | 0.010 |
Why?
|
| Adenosine Diphosphate | 2 | 1985 | 66 | 0.010 |
Why?
|
| Diet, Diabetic | 1 | 1994 | 14 | 0.010 |
Why?
|
| Platelet Factor 4 | 1 | 1994 | 10 | 0.010 |
Why?
|
| Arachidonic Acids | 2 | 1985 | 97 | 0.010 |
Why?
|
| Rats, Inbred Strains | 2 | 1985 | 532 | 0.010 |
Why?
|
| Serotonin | 2 | 1985 | 144 | 0.010 |
Why?
|
| Thrombin | 2 | 1985 | 117 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1995 | 1040 | 0.010 |
Why?
|
| Agammaglobulinemia | 1 | 1970 | 3 | 0.010 |
Why?
|
| Cryoglobulins | 1 | 1970 | 4 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1970 | 9 | 0.010 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1970 | 10 | 0.010 |
Why?
|
| Propionates | 1 | 1970 | 21 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1970 | 79 | 0.010 |
Why?
|
| Glycine | 1 | 1970 | 89 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1970 | 69 | 0.010 |
Why?
|
| Polymers | 1 | 1970 | 244 | 0.000 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1985 | 17 | 0.000 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1985 | 31 | 0.000 |
Why?
|
| Ristocetin | 1 | 1985 | 3 | 0.000 |
Why?
|
| Thromboxane A2 | 1 | 1985 | 88 | 0.000 |
Why?
|
| Endotoxins | 1 | 1985 | 76 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1985 | 324 | 0.000 |
Why?
|
| Lipoproteins, IDL | 1 | 1983 | 8 | 0.000 |
Why?
|
| Plasminogen Activators | 1 | 1983 | 19 | 0.000 |
Why?
|
| Platelet Function Tests | 1 | 1983 | 10 | 0.000 |
Why?
|
| Zymosan | 1 | 1983 | 12 | 0.000 |
Why?
|
| Phospholipases A2 | 1 | 1983 | 32 | 0.000 |
Why?
|
| Epoprostenol | 1 | 1983 | 71 | 0.000 |
Why?
|
| Phospholipases A | 1 | 1983 | 41 | 0.000 |
Why?
|
| Indomethacin | 1 | 1983 | 107 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1985 | 458 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1980 | 89 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1980 | 166 | 0.000 |
Why?
|
| Hemoglobinuria | 1 | 1979 | 2 | 0.000 |
Why?
|
| Platelet Adhesiveness | 1 | 1979 | 20 | 0.000 |
Why?
|
| Capillary Permeability | 1 | 1979 | 69 | 0.000 |
Why?
|
| Lasers | 1 | 1979 | 61 | 0.000 |
Why?
|
| Arteries | 1 | 1979 | 108 | 0.000 |
Why?
|
| Plasma Cells | 1 | 1978 | 19 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1978 | 168 | 0.000 |
Why?
|